🇺🇸 FDA
Pipeline program

VX-670

VX24-670-101

Phase 2 small_molecule active

Quick answer

VX-670 for Myotonic Dystrophy Type 1 (DM1) is a Phase 2 program (small_molecule) at VERTEX PHARMACEUTICALS INC / MA with 2 ClinicalTrials.gov record(s).

Program details

Company
VERTEX PHARMACEUTICALS INC / MA
Indication
Myotonic Dystrophy Type 1 (DM1)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials